These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 8225242

  • 1. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
    Hurlimann J, Gebhard S, Gomez F.
    Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
    [Abstract] [Full Text] [Related]

  • 2. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A, Argibay S, Arias JI, Ruibal A.
    Rev Esp Med Nucl; 2005 Sep; 24(3):185-90. PubMed ID: 15847785
    [Abstract] [Full Text] [Related]

  • 3. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
    Ioachim E, Tsanou E, Briasoulis E, Batsis Ch, Karavasilis V, Charchanti A, Pavlidis N, Agnantis NJ.
    Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
    [Abstract] [Full Text] [Related]

  • 4. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
    Marsigliante S, Biscozzo L, Correale M, Paradiso A, Leo G, Abbate I, Dragone CD, Storelli C.
    Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
    [Abstract] [Full Text] [Related]

  • 5. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
    Ruibal A, Arias JI, Resino C, Lapeña G, Schneider J, Tejerina A.
    Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
    [Abstract] [Full Text] [Related]

  • 6. [Infiltrating ductal carcinomas of the breast in women over 60 years of age. Association with higher cellular proliferation and lower PS2, cell surface and cytosolic hyaluronic acid concentrations].
    Ruibal A, Arias J, Del Río MC, Resino C, Tejerina A.
    Rev Esp Med Nucl; 2001 Dec; 20(7):525-9. PubMed ID: 11709137
    [Abstract] [Full Text] [Related]

  • 7. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ, Scharl A, Ahr A.
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [Abstract] [Full Text] [Related]

  • 8. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O, Bruscagnin G.
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [Abstract] [Full Text] [Related]

  • 9. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
    Tamargo F, Vizoso F, Lamelas ML, Rodil A, Vérez P, Raigoso P, Mulero M, Vázquez J, Roiz C, Allende MT.
    Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
    [Abstract] [Full Text] [Related]

  • 10. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
    Ahr A, Scharl A, Göhring UJ, Crombach G, Stoffl M.
    Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
    [Abstract] [Full Text] [Related]

  • 11. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I, Quénel N, Coindre JM, Bonichon F, Durand M, Wafflart J, Mauriac L.
    Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
    Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJ, Neoptolemos JP.
    Eur J Cancer; 1994 Oct; 30A(1):5-11. PubMed ID: 8142164
    [Abstract] [Full Text] [Related]

  • 14. [Cytosolic concentrations of cathepsin D in 88 infiltrating ductal breast carcinomas having negative estrogen and progesterone receptors. Correlation with other clinical and biological parameters].
    Ruibal A, Arias J, Lapeña G, García Díez S, Tejerina A.
    Rev Esp Med Nucl; 2001 Jun; 20(4):332-3. PubMed ID: 11940423
    [No Abstract] [Full Text] [Related]

  • 15. Estrogen and progesterone receptors and pS2 and ERD5 antigens in gastric carcinomas from the European population.
    Chaubert P, Bouzourene H, Saraga E.
    Mod Pathol; 1996 Mar; 9(3):189-93. PubMed ID: 8685212
    [Abstract] [Full Text] [Related]

  • 16. [Hormone-dependent, diploid, infiltrating ductal breast carcinomas less than 2 cm in size: influence of an exclusive and moderate cellular proliferation on the clinicobiological features and recurrences of these malignant tumors].
    Ruibal A, Arias JI.
    Rev Esp Med Nucl; 2002 Mar; 21(6):437-8. PubMed ID: 12425893
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas.
    Weber-Chappuis K, Bieri-Burger S, Hurlimann J.
    Eur J Cancer; 1996 Sep; 32A(10):1686-92. PubMed ID: 8983275
    [Abstract] [Full Text] [Related]

  • 18. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A, Schneider J, Arias J, del Río MC, Núnez MJ, Tejerina A.
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Clinico-biological impact of pS2 positivity in estrogen receptor negative-infiltrating ductal carcinomas of the breast].
    Ruibal A, Arias J, del Río MC, San Román JM, Lapeña G, Pardo C, Tejerina A.
    Rev Esp Med Nucl; 2000 Oct; 19(6):428-33. PubMed ID: 11060273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.